News & Events

February 12, 2018

Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support the Clinical Development of a Novel Parkinson’s Therapy

SAN CARLOS, Calif. — Alkahest Inc., a privately held, clinical stage biopharmaceutical company focused on neurodegenerative and other age-related diseases, announced today that is has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support a... Continue Reading

January 23, 2018

Alkahest, Inc. Announces Key Appointments

SAN CARLOS, Calif. — Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointments of Karl G. Trass as Vice President, Regulatory Affairs and Jonas... Continue Reading

November 10, 2017

Alkahest to Present at Society for Neuroscience 47th Annual Meeting

SAN CARLOS, Calif. — Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience 47th Annual Meeting, taking place November 11-15, 2017 in... Continue Reading

November 1, 2017

Alkahest to Present Clinical Results from PLASMA Study in Patients with Mild to Moderate Alzheimer’s Disease at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN CARLOS, Calif. — Alkahest, Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced an upcoming oral presentation at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The... Continue Reading

August 7, 2017

Alkahest Appoints Helen Jenkins as Chief Operating Officer

SAN CARLOS, Calif. — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today that Helen Jenkins, has joined the company’s executive team as Chief Operating... Continue Reading

January 23, 2017

Alkahest Appoints Sam Jackson, M.D., MBA as Chief Medical Officer

SAN CARLOS, Calif. — Alkahest Inc. (“Alkahest”), a biotechnology company focused on developing innovative treatments for neurodegenerative diseases and other age-related conditions, announced today that Sam Jackson, MD, MBA, has joined the company as Chief Medical Officer. In this role,... Continue Reading